Condition
Idiopathic Dilated Cardiomyopathy
Total Trials
5
Recruiting
1
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (2)
P 4 (1)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03037632Not ApplicableActive Not RecruitingPrimary
DCM Precision Medicine Study
NCT06356727Not ApplicableRecruiting
Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling
NCT01798992Phase 4CompletedPrimary
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
NCT02033278Phase 2TerminatedPrimary
Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.
NCT02987322Phase 2CompletedPrimary
Honey in Idiopathic Dilated Cardiomyopathy
Showing all 5 trials